2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. Inc. (MRK) based on the data provided.

**1) Return Rate Comparison**

*   **Company Overview:** Merck & Co Inc is a global pharmaceutical company.
*   **MRK Cumulative Return:** 21.74%
*   **VOO (S&P 500) Cumulative Return:** 105.07%
*   **Divergence:** -83.33 (Relative Divergence: 21.7)

**Analysis:** MRK has significantly underperformed the S&P 500 over the period examined. The negative divergence of -83.33 indicates a substantial difference in cumulative returns. The relative divergence of 21.7 suggests the current divergence is closer to the minimum observed over the examined period. It is in the bottom quartile.

**Alpha, Beta Analysis:**

| Year      | CAGR | MDD  | Alpha | Beta | Cap(B) |
|-----------|------|------|-------|------|--------|
| 2016-2018 | 51.0% | 69.5% | 22.0% | 0.7  | 182.1  |
| 2017-2019 | 47.0% | 69.5% | 5.0%  | 0.7  | 216.8  |
| 2018-2020 | 38.0% | 81.8% | 5.0%  | 0.7  | 195.0  |
| 2019-2021 | 8.0%  | 81.8% | -68.0% | 0.6  | 191.4  |
| 2020-2022 | 36.0% | 81.0% | 17.0% | 0.5  | 277.1  |
| 2021-2023 | 48.0% | 80.2% | 20.0% | 0.3  | 272.3  |
| 2022-2024 | 22.0% | 80.2% | -8.0% | 0.3  | 248.5  |
| 2023-2025 | -2.0% | 80.8% | -70.0% | 0.3  | 262.9  |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate (CAGR) has fluctuated significantly.  There was strong growth between 2016-2023 and a decline for 2023-2025.
*   **MDD:** The Maximum Drawdown (MDD) indicates substantial risk, consistently above 69.5%. The high MDD might concern risk-averse investors.
*   **Alpha:**  Alpha, which measures performance relative to the benchmark, shows periods of both outperformance (positive Alpha) and underperformance (negative Alpha).  The recent negative Alpha values suggest the stock hasn't been performing as well as expected relative to the market.
*   **Beta:** Beta is trending lower, indicating decreasing volatility relative to the market. Merck's beta is 0.3, so it is less volatile than the S\&P 500 index.
*   **Capitalization:** The market capitalization (Cap) has generally increased over time.

**2) Recent Stock Price Fluctuations**

*   **Close Price:** 105.26
*   **Last Market Data:** Price: 105.26, Previous Close: 106.06, Change: -0.75
*   **5-day SMA:** 106.234
*   **20-day SMA:** 101.8025
*   **60-day SMA:** 94.1685

**Analysis:** The stock price closed at 105.26, a slight decrease from the previous close.  The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This is generally a bullish sign, although the recent price decrease needs to be considered. The fact that the 5-day SMA is highest indicates that the stock price is at a relative short term low.

**3) Technical Indicators & Market Risk**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 75.92 (Overbought)
*   **PPO:** 0.1233
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-12-24)
*   **Recent (20 days) relative divergence change:** 1.7 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** 0.0

**Analysis:**

*   **MRI:** The high MRI suggests the market considers Merck a relatively safe investment currently.
*   **RSI:**  The RSI above 70 indicates the stock is overbought and may be due for a correction (price decrease).
*   **PPO:**  The Positive Phase Oscillator (PPO) is a momentum oscillator used to determine the convergence and divergence of two moving averages. PPO values above zero indicate that the shorter moving average is above the longer moving average.
*   **Hybrid Signal:** The signal suggests buying the stock with 100% of available cash, rating it as very safe. This is influenced by the high MRI.
*   **Divergence Change:** Recent increase in relative divergence (+1.7) indicates a short-term upward trend.
*   **Expected Return:** The 0.0% expected return suggests that analysts do not expect Merck to outperform the S&P 500 over the long term.

**4) Recent News & Significant Events**

*   **[2025-12-16] Morgan Stanley raised Merck's price target** citing an improved outlook for biopharma.
*   **[2026-01-01] News about market closure** and investors' focus on upcoming events.
*   **[2026-01-01] "Merck: Framework For Success"**:  Likely a bullish article on Seeking Alpha, suggesting a positive outlook on Merck's strategic positioning.
*   **[2026-01-01] Northwest Capital Management Inc. Sold Shares:** Could be a negative signal if interpreted as a lack of confidence.
*   **[2025-12-30] Comparison to Peers:** Suggests analysis of Merck's relative valuation and performance within its industry.
*   **[2025-11-26] Reasons for Stock Surge:** Indicates a recent positive catalyst driving the stock price up.

**Analysis:** The news is mixed. The price target increase from Morgan Stanley is positive. The article "Merck: Framework for Success" suggests a positive long-term outlook.  However, the news of Northwest Capital Management selling shares is potentially negative.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.90)
*   **Target Price:** Avg: 110.04 / High: 139.00 / Low: 83.00
*   **Recent Rating Changes:** Not provided

**Analysis:**  The analyst consensus is a "Buy" with an average target price of $110.04. This suggests analysts believe the stock is undervalued.  However, there is a wide range in target prices, indicating some uncertainty.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|-----------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

**Analysis:**

*   EPS (Earnings Per Share) generally increased across the provided dates.
*   Revenue shows fluctuations, with the most recent quarter showing the highest revenue.
* It seems that data "2024-11-06" and "2025-11-05" are duplicated.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $17.28B    | 77.69%        |
| 2025-06-30 | $15.81B    | 77.50%        |
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-09-30 | $51.85B    | 11.16% |
| 2025-06-30 | $48.99B    | 9.04%  |
| 2025-03-31 | $48.34B    | 10.51% |
| 2024-12-31 | $46.31B    | 8.08%  |
| 2024-09-30 | $44.50B    | 7.09%  |

**Analysis:**

*   **Revenue:**  Revenue has shown a general upward trend.
*   **Profit Margin:** The profit margin is very high and consistently around 75%+, indicating strong profitability.
*   **Equity:**  Equity has been increasing, indicating growth in the company's assets.
*   **ROE:** Return on Equity (ROE) has also generally increased, indicating improving profitability relative to shareholders' equity.

**7) Comprehensive Analysis**

Merck (MRK) presents a mixed picture. While the company's financials (revenue, profit margin, equity, ROE) are strong and generally trending positively, its stock price has significantly underperformed the S&P 500. The negative Alpha in recent periods supports this underperformance.

Technically, the stock is currently overbought (high RSI), suggesting a potential pullback.  The moving averages show a short-term upward trend, but the negative price change in the last market day is a caution sign.

Analyst opinions are generally positive (Buy consensus and a higher average target price), indicating potential upside. However, negative news like Northwest Capital Management selling shares temper this bullish outlook.

The MRI indicates a relatively safe investment, and the hybrid signal is a strong buy recommendation. However, this might be misleading as the high RSI indicates an overbought stock.

**Overall, Merck is a fundamentally strong company with some positive catalysts (Morgan Stanley price target increase), but the current stock price may be overvalued in the short term. While the long-term expected return is not higher than S&P 500, it might be a good investment for risk-averse investors, given the high MRI.**

**Recommendation:** Consider waiting for a potential price correction before initiating a long position. Closely monitor news and analyst ratings for further developments. This is not financial advice, but an interpretation of provided data points.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.